

Mariano Provencio Pulla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629678/publications.pdf>

Version: 2024-02-01

246
papers

18,387
citations

34493

54
h-index

15698

129
g-index

256
all docs

256
docs citations

256
times ranked

20534
citing authors

#	ARTICLE	IF	CITATIONS
1	Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study. Archivos De Bronconeumologia, 2022, 58, 542-546.	0.4	10
2	Fruits and Vegetables and Lung Cancer Risk in Never Smokers. A Multicentric and Pooled Case-Control Study. Nutrition and Cancer, 2022, 74, 613-621.	0.9	2
3	Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 188-200.	1.3	6
4	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	3.2	9
5	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	13.9	871
6	Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. Cancers, 2022, 14, 2158.	1.7	3
7	Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy. Oncogenesis, 2022, 11, 24.	2.1	7
8	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 711-728.	1.8	12
9	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Journal of Clinical Oncology, 2022, 40, 2924-2933.	0.8	127
10	Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Molecular Oncology, 2021, 15, 43-56.	2.1	18
11	Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group. Hematological Oncology, 2021, 39, 506-512.	0.8	2
12	Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2021, 60, 81-88.	0.6	37
13	Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer, 2021, 21, 230.	1.1	9
14	ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1221-1229.	1.4	7
15	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer, 2021, 153, 25-34.	0.9	17
16	The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. Biomedicines, 2021, 9, 361.	1.4	7
17	Residential radon and lung cancer characteristics at diagnosis. International Journal of Radiation Biology, 2021, 97, 997-1002.	1.0	4
18	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2193-2204.	1.3	16

#	ARTICLE	IF	CITATIONS
19	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-“positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. <i>European Journal of Cancer</i> , 2021, 149, 61-72.	1.3	21
20	Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. <i>Translational Lung Cancer Research</i> , 2021, 10, 2588-2602.	1.3	5
21	NGS-“based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. <i>Molecular Oncology</i> , 2021, 15, 2363-2376.	2.1	16
22	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. , 2021, 9, e002323.		26
23	Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2715-2732.	1.3	11
24	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	1.7	26
25	Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-III A) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. <i>Cancer Research</i> , 2021, 81, CT003-CT003.	0.4	74
26	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. <i>Lung Cancer Management</i> , 2021, 10, LMT51.	1.5	10
27	Lung cancer patients with COVID-19 in Spain: GRAVID study. <i>Lung Cancer</i> , 2021, 157, 109-115.	0.9	24
28	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. <i>Future Oncology</i> , 2021, 17, 4011-4025.	1.1	10
29	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. <i>BMC Cancer</i> , 2021, 21, 977.	1.1	5
30	Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 86.	1.3	10
31	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5878-5890.	3.2	30
32	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
33	R-Score: A New Parameter to Assess the Quality of Variants-“™ Calls Assessed by NGS Using Liquid Biopsies. <i>Biology</i> , 2021, 10, 954.	1.3	1
34	Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. <i>Cancers</i> , 2021, 13, 4622.	1.7	6
35	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	1.3	12
36	Are there differences by sex in lung cancer characteristics at diagnosis? -“a nationwide study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3902-3911.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Next-generation sequencing for tumor mutation quantification using liquid biopsies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 306-313.	1.4	10
38	ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2020, 9, 532-540.	1.3	17
39	Lung cancer symptoms at diagnosis: results of a nationwide registry study. <i>ESMO Open</i> , 2020, 5, e001021.	2.0	15
40	Lung cancer risk and residential radon exposure: A pooling of case-control studies in northwestern Spain. <i>Environmental Research</i> , 2020, 189, 109968.	3.7	38
41	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1413-1422.	5.1	475
42	A Data-Driven Approach for Analyzing Healthcare Services Extracted from Clinical Records. , 2020, , .		2
43	Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 366-372.	1.3	19
44	Reconstructing the patient's natural history from electronic health records. <i>Artificial Intelligence in Medicine</i> , 2020, 105, 101860.	3.8	14
45	Clinical utility of liquid biopsy for the diagnosis and monitoring of <i>EML4-ALK</i> NSCLC patients. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
46	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
47	Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. <i>Cancer Epidemiology</i> , 2020, 67, 101737.	0.8	15
48	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	1.3	16
49	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2696-2715.	1.3	43
50	Utilidad cl�nica de la biopsia l�quida para el diagn�stico y seguimiento de los pacientes con CPNM y <i>EML4-ALK</i> . <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
51	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. <i>Revista Espanola De Patologia</i> , 2020, 53, 140-148.	0.6	0
52	ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	1.1	42
53	Residential radon, genetic polymorphisms in DNA damage and repair-related. <i>Lung Cancer</i> , 2019, 135, 10-15.	0.9	21
54	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). <i>Translational Lung Cancer Research</i> , 2019, 8, 461-475.	1.3	38

#	ARTICLE	IF	CITATIONS
55	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	2.0	38
56	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
57	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78
58	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. <i>European Journal of Cancer</i> , 2019, 116, 137-147.	1.3	167
59	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.	0.8	170
60	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
61	Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1 β in NSCLC which can be overcome by OXPBOS inhibition. <i>Free Radical Biology and Medicine</i> , 2019, 135, 167-181.	1.3	108
62	Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain. <i>Environmental Research</i> , 2019, 172, 713-718.	3.7	60
63	Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. <i>Hematological Oncology</i> , 2019, 37, 143-150.	0.8	9
64	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 34.	2.8	23
65	How we treat patients with lung cancer during the SARS-CoV-2 pandemic. <i>ESMO Open</i> , 2019, 4, e000785.	2.0	2
66	Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. <i>Leukemia and Lymphoma</i> , 2019, 60, 856-859.	0.6	4
67	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 304-310.	0.5	10
68	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296.	0.6	55
69	Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- β 2 signaling. <i>Free Radical Biology and Medicine</i> , 2019, 130, 163-173.	1.3	91
70	Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies. <i>Pathology Research and Practice</i> , 2019, 215, 392-394.	1.0	11
71	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
72	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
74	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	0.6	0
75	A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. <i>Clinical and Translational Oncology</i> , 2019, 21, 489-498.	1.2	65
76	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.	0.7	6
77	Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies. <i>European Journal of Public Health</i> , 2018, 28, 521-527.	0.1	13
78	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
79	Características al diagnóstico y supervivencia de estadios I y II de cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2018, 54, 420-426.	0.4	4
80	Lung cancer in lung transplantation: incidence and outcome. <i>Postgraduate Medical Journal</i> , 2018, 94, 15-19.	0.9	22
81	Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 488-494.	0.8	30
82	Profiling Lung Cancer Patients Using Electronic Health Records. <i>Journal of Medical Systems</i> , 2018, 42, 126.	2.2	17
83	An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement. <i>PLoS ONE</i> , 2018, 13, e0193233.	1.1	9
84	Hyperprogression as a distinct outcome after immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 16-21.	3.4	89
85	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	1.1	9
86	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2018, 24, 5543-5551.	3.2	18
87	Long-term follow up of Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 11638-11645.	0.8	7
88	Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib. <i>Annals of Translational Medicine</i> , 2018, 6, S31-S31.	0.7	0
89	Association of DDX58 polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosing classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 438-444.	0.6	2
90	Follicular lymphomas and their transformation: Past and current research. <i>Expert Review of Hematology</i> , 2017, 10, 515-524.	1.0	8

#	ARTICLE	IF	CITATIONS
91	Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 1647-1654.	0.8	5
92	Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. <i>Cancer</i> , 2017, 123, 3709-3716.	2.0	23
93	Exercise and the Hallmarks of Cancer. <i>Trends in Cancer</i> , 2017, 3, 423-441.	3.8	124
94	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	0.9	18
95	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.	0.6	9
96	Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study. <i>Cancer Letters</i> , 2017, 411, 130-135.	3.2	9
97	El tumor del estroma gastrointestinal y la aparición de segundos tumores: revisión de la bibliografía. <i>Medicina Clínica</i> , 2017, 149, 345-350.	0.3	7
98	Cáncer de pulmón microcítico. Metodología y resultados preliminares del estudio SMALL CELL. <i>Archivos De Bronconeumología</i> , 2017, 53, 675-681.	0.4	5
99	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
100	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	128
101	PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy. <i>Scientific Reports</i> , 2017, 7, 16661.	1.6	21
102	Small Cell Lung Cancer. Methodology and Preliminary Results of the SMALL CELL Study. <i>Archivos De Bronconeumología</i> , 2017, 53, 675-681.	0.4	0
103	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.	1.1	5
104	Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 186-191.	0.2	29
105	Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK). <i>ADMET and DMPK</i> , 2017, 5, 1.	1.1	0
106	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 102888-102897.	0.8	22
107	Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2843-2846.	0.6	0
108	Copanlisib in patients with relapsed or refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7535-7535.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. PLoS ONE, 2017, 12, e0177204.	1.1	18
110	mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. Oncotarget, 2017, 8, 50949-50957.	0.8	31
111	Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. Oncotarget, 2017, 8, 59408-59416.	0.8	12
112	Dynamic circulating tumor DNA quantification for the individualization of non-small-cell lung cancer patients treatment. Oncotarget, 2017, 8, 60291-60298.	0.8	22
113	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget, 2017, 8, 111386-111395.	0.8	33
114	Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Translational Lung Cancer Research, 2016, 5, 455-465.	1.3	79
115	CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3 β signaling pathway. Oncotarget, 2016, 7, 68781-68791.	0.8	51
116	Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Translational Lung Cancer Research, 2016, 5, 665-672.	1.3	114
117	Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. European Respiratory Journal, 2016, 48, 1462-1470.	3.1	32
118	Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. Molecular and Clinical Oncology, 2016, 4, 93-99.	0.4	2
119	Small cell lung cancer in never-smokers. European Respiratory Journal, 2016, 47, 947-953.	3.1	32
120	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. Anticancer Research, 2016, 36, 6647-6654.	0.5	9
121	Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk. Journal of Thoracic Oncology, 2015, 10, 1279-1284.	0.5	27
122	Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience, 2015, 2, 131-141.	0.9	57
123	HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01:02. PLoS ONE, 2015, 10, e0135512.	1.1	9
124	High-dose Chemotherapy Followed by Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Follicular Non-Hodgkin's Lymphoma in the Rituximab Era. Tumori, 2015, 101, 2-7.	0.6	1
125	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treatment Reviews, 2015, 41, 680-689.	3.4	43
126	Sentinel lymph node biopsy in breast cancer: the role of micrometastasis. Medical Oncology, 2015, 32, 450.	1.2	1

#	ARTICLE	IF	CITATIONS
127	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1286-1294.	0.6	10
128	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015, 54, 933-938.	0.8	11
129	Insight in paranoia: The role of experiential avoidance and internalized stigma. <i>Schizophrenia Research</i> , 2015, 164, 214-220.	1.1	27
130	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <i>Cancer Epidemiology</i> , 2015, 39, 291-297.	0.8	39
131	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	5.1	124
132	Residential radon and lung cancer characteristics in never smokers. <i>International Journal of Radiation Biology</i> , 2015, 91, 605-610.	1.0	23
133	Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1686-1690.	0.6	5
134	Exosomes enriched in stemness/metastatic-related mRNAs promote oncogenic potential in breast cancer. <i>Oncotarget</i> , 2015, 6, 40575-40587.	0.8	70
135	Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e98169.	1.1	31
136	Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 51-55.	0.6	21
137	High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1413-1416.	0.6	5
138	Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 78-90.	1.1	6
139	Different exosome cargo from plasma/bronchoalveolar lavage in non-small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 713-724.	1.5	121
140	New drugs and targeted treatments in Hodgkin's lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 457-464.	3.4	10
141	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	1.7	2
142	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	0.6	193
143	Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 89-94.	1.3	16
144	Cancer-associated fibroblast and α 2 macrophage markers together predict outcome in colorectal cancer patients. <i>Cancer Science</i> , 2013, 104, 437-444.	1.7	235

#	ARTICLE	IF	CITATIONS
145	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. <i>Medical Oncology</i> , 2013, 30, 572.	1.2	21
146	False-positive interpretations in respiratory cytopathology. <i>Clinical Rheumatology</i> , 2013, 32, 15-17.	1.0	1
147	Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-24.	3.3	28
148	Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab. <i>Case Reports in Oncology</i> , 2012, 5, 676-681.	0.3	9
149	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
150	Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. <i>Cancer Treatment Reviews</i> , 2012, 38, 36-53.	3.4	57
151	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012, 76, 354-361.	0.9	29
152	Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 553-561.	0.6	11
153	Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?. <i>Clinical and Translational Oncology</i> , 2012, 14, 386-390.	1.2	4
154	Breast cancer occurred after Hodgkin's disease: Clinico-pathological features, treatments and outcome: Analysis of 214 cases. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 29-37.	2.0	29
155	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. <i>Investigational New Drugs</i> , 2012, 30, 729-740.	1.2	36
156	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-14.	0.6	16
157	Predictors of subjective well-being in patients with paranoid symptoms: Is insight necessarily advantageous?. <i>Psychiatry Research</i> , 2011, 189, 190-194.	1.7	26
158	Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin lymphoma. <i>Histopathology</i> , 2011, 59, 349-352.	1.6	5
159	Activity of trabectedin in desmoplastic small round cell tumor. <i>Medical Oncology</i> , 2011, 28, 644-646.	1.2	21
160	PET-CT in the staging and treatment of non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 368-377.	1.2	16
161	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011, 13, 411-418.	1.2	0
162	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 1160-1168.	3.2	292

#	ARTICLE	IF	CITATIONS
163	Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications. <i>Leukemia and Lymphoma</i> , 2011, 52, 2162-2168.	0.6	14
164	Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. <i>European Respiratory Journal</i> , 2011, 37, 617-623.	3.1	260
165	Implicit and explicit self-esteem discrepancies in paranoia and depression.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 691-699.	2.0	45
166	Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 179-187.	0.6	13
167	Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , 2011, 3, 197-204.	0.6	44
168	New molecular targeted therapies for advanced non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2011, 3, 30-56.	0.6	29
169	Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 384-386.	1.2	1
170	Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. <i>Clinical and Translational Oncology</i> , 2010, 12, 701-703.	1.2	8
171	SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 753-759.	1.2	2
172	SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 765-769.	1.2	1
173	New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 91-97.	1.1	56
174	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
175	Old and New Insights in the Treatment of Thyroid Carcinoma. <i>Journal of Thyroid Research</i> , 2010, 2010, 1-16.	0.5	9
176	Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-17.	3.0	13
177	Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 2021-2030.	0.6	8
178	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	0.9	8
179	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.	0.9	13
180	Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-6.	0.6	15

#	ARTICLE	IF	CITATIONS
181	A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1642-1646.	0.6	8
182	Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients. <i>Clinical Cancer Research</i> , 2009, 15, 4823-4828.	3.2	12
183	Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. <i>Clinical and Translational Oncology</i> , 2009, 11, 35-40.	1.2	9
184	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.	1.2	14
185	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 428-436.	1.2	4
186	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	1.2	3
187	Lung cancer and treatment in elderly patients: The Achilles Study. <i>Lung Cancer</i> , 2009, 66, 103-106.	0.9	18
188	Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?. <i>Clinical Lung Cancer</i> , 2009, 10, 295-300.	1.1	23
189	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	13.9	2,213
190	Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. <i>PLoS ONE</i> , 2009, 4, e5133.	1.1	153
191	Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. <i>PLoS ONE</i> , 2009, 4, e8173.	1.1	26
192	Circulating tumor cells in breast cancer: methodology and clinical repercussions. <i>Clinical and Translational Oncology</i> , 2008, 10, 399-406.	1.2	8
193	Hodgkin's disease and intercurrent processes that may simulate a relapse. <i>Clinical and Translational Oncology</i> , 2008, 10, 439-441.	1.2	1
194	R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. <i>Hematological Oncology</i> , 2008, 26, 27-32.	0.8	15
195	A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. <i>Clinical Breast Cancer</i> , 2008, 8, 149-154.	1.1	34
196	Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5300-5305.	3.2	11
197	Flumazenil in the Treatment of Dizziness and Vegetative Symptoms after Intravenous Infusion of Paclitaxel. <i>Onkologie</i> , 2008, 31, 203-203.	1.1	1
198	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2008, 14, 4794-4799.	3.2	99

#	ARTICLE	IF	CITATIONS
199	Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of an International Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2008, 3, 994-1002.	0.5	48
200	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	0.8	445
201	Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , 2007, 25, 4736-4742.	0.8	104
202	P3-080: Erlotinib as single agent in men with advanced or metastatic NSCLC: A retrospective analysis. <i>Journal of Thoracic Oncology</i> , 2007, 2, S712-S713.	0.5	3
203	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 662-668.	0.6	131
204	Extracellular tumor DNA in plasma and overall survival in breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 692-701.	1.5	41
205	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006, 17, 467-472.	0.6	117
206	Implication of Polycomb Members Bmi-1, Mel-18, and Hpc-2 in the Regulation of p16INK4a, p14ARF, h-TERT, and c-Myc Expression in Primary Breast Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 6929-6936.	3.2	76
207	Rapid-infusion rituximab in lymphoma treatment. <i>Annals of Oncology</i> , 2006, 17, 1027-1028.	0.6	25
208	Association Between Hepatitis C Virus and Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 3513-3513.	0.8	2
209	Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential. <i>Clinical Cancer Research</i> , 2006, 12, 2095-2100.	3.2	35
210	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 1318-1325.	3.2	345
211	Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 554, 215-221.	0.4	13
212	Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomas. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 257-262.	1.5	7
213	Promoter methylation of the PTEN gene is a common molecular change in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 117-124.	1.5	196
214	Prognostic Factors in Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2004, 45, 1133-1139.	0.6	12
215	Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. <i>Annals of Surgical Oncology</i> , 2003, 10, 150-154.	0.7	129
216	Targeted therapy in combination with gemcitabine in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 19-25.	0.8	34

#	ARTICLE	IF	CITATIONS
217	Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. <i>Journal of Pathology</i> , 2003, 199, 289-297.	2.1	100
218	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	0.8	420
219	Intratumoral Heterogeneity in Microsatellite Alterations in BRCA1 and PTEN Regions in Sporadic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 876-881.	0.7	13
220	The Management of Stage III Supradiaphragmatic Hodgkin's Disease with Chemotherapy Alone. <i>Leukemia and Lymphoma</i> , 2003, 44, 263-268.	0.6	4
221	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	0.8	177
222	Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. <i>Gut</i> , 2002, 50, 530-534.	6.1	124
223	Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. <i>Annals of Surgical Oncology</i> , 2002, 9, 71-76.	0.7	61
224	p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. <i>Clinical Cancer Research</i> , 2002, 8, 980-5.	3.2	84
225	Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. <i>Clinical Cancer Research</i> , 2002, 8, 3761-6.	3.2	97
226	Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. <i>Radiotherapy and Oncology</i> , 2001, 59, 247-255.	0.3	92
227	Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 183-190.	1.1	52
228	Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. <i>Oncogene</i> , 2001, 20, 4586-4590.	2.6	46
229	Hodgkin's Disease: Unsuspected Minimal Activity in Patients that Die from Causes Other than Tumoral Progression. <i>Leukemia and Lymphoma</i> , 2001, 42, 661-664.	0.6	4
230	Breast cancer: contribution of molecular biology to the management of the disease. , 2001, 3, 130-136.		2
231	Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance. <i>Annals of Oncology</i> , 2000, 11, 1097-1104.	0.6	81
232	DNA damage after chemotherapy correlates with tumor response and survival in small cell lung cancer patients. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000, 456, 65-71.	0.4	5
233	Clinicopathological characteristics of breast carcinomas with allelic loss in the p73. <i>Breast Cancer Research and Treatment</i> , 2000, 63, 17-22.	1.1	8
234	Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. <i>British Journal of Cancer</i> , 2000, 82, 1183-1185.	2.9	40

#	ARTICLE	IF	CITATIONS
235	Metastatic Renal Cell Carcinoma to the Head and Neck Area. Tumori, 2000, 86, 88-90.	0.6	17
236	Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. British Journal of Cancer, 1999, 80, 1262-1264.	2.9	116
237	Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. British Journal of Cancer, 1999, 81, 503-509.	2.9	70
238	Loss of heterozygosity in BRCA1 and BRCA2 markers and high grade malignancy in breast cancer. Breast Cancer Research and Treatment, 1999, 53, 9-17.	1.1	31
239	Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Research and Treatment, 1999, 57, 237-243.	1.1	104
240	Low Incidence of Germline BRCA2 Gene Mutations among Spanish Breast Cancer Patients. Oncology, 1999, 57, 173-174.	0.9	4
241	Loss of Heterozygosity in the Region Including the BRCA1 Gene on 17q in Colon Cancer. Cancer Genetics and Cytogenetics, 1998, 104, 119-123.	1.0	36
242	BRCA1 Mutations in Patients with Familial Risk of Breast Cancer. Acta Oncológica, 1998, 37, 299-300.	0.8	0
243	Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.. Journal of Clinical Oncology, 1998, 16, 115-120.	0.8	34
244	Breast Angiosarcoma After Radiation Therapy. Acta Oncológica, 1995, 34, 969-969.	0.8	23
245	Malignant Fibrous Histiocytoma of the Spleen and Chronic Myelogenous Leukemia. Oncology, 1994, 51, 465-466.	0.9	13
246	Pneumomediastinum after belching. Lancet, The, 1990, 336, 1390.	6.3	3